Weight Loss Drugs in France: Options, Side Effects & Medical Approval

The quest for effective weight loss solutions in France continues to evolve, with a growing interest in medications designed to aid this process. As of March 2026, several options are available, but they are specifically intended for individuals facing obesity or significant weight-related health complications, not simply for those seeking to lose a few kilograms. This article explores the current landscape of weight loss medications in France, outlining who can access them, how they work, and the important considerations surrounding their use.

Understanding the Options: Mounjaro®, Wegovy®, and Saxenda®

Currently, the primary medications available in France for weight management are Mounjaro®, Wegovy®, and Saxenda®. These are administered via injection and are designed to be used in conjunction with a tailored diet and increased physical activity. Their core mechanism involves appetite suppression. As Dr. Arnaud Cocaul, a nutritionist, explains, these medications help patients consume less food, leading to potentially significant weight loss – some individuals experiencing reductions of 20 to 25 kilograms. This effect is largely “mechanical,” reducing intake and body weight.

However, it’s crucial to understand that these medications aren’t without potential side effects. The most common are digestive issues, including nausea, vomiting, diarrhea, and constipation. The cost of these treatments can be substantial, as they are generally not covered by public health insurance. It’s also important to note that these are not intended as lifelong solutions; weight regain is possible upon discontinuation, highlighting the need for sustained lifestyle changes.

The Role of Ozempic and Orlistat

Ozempic, even as also effective for weight loss, is currently authorized in France only for patients with diabetes. It belongs to the same family of medications as Mounjaro®, Wegovy®, and Saxenda® and operates through similar mechanisms. Another option, orlistat (marketed as Xenical®), works differently by reducing the absorption of fats in the intestine. However, its effectiveness is considerably more limited, typically resulting in a maximum weight loss of around 5% – for example, a 70-kilogram individual might lose 3.5 kilograms. Orlistat also carries digestive side effects, including oily stools and fecal incontinence, and is becoming less frequently prescribed in favor of the newer injectable medications.

You can discover more information about the side effects of vomiting from Journal des Femmes.

Eligibility and the Importance of Medical Evaluation

Access to these weight loss medications is not open to everyone. Eligibility is determined by Body Mass Index (BMI). A BMI between 25 and 29.9 indicates overweight, while a BMI of 30 or higher signifies obesity. Before any prescription is considered, a thorough medical evaluation is essential to determine the underlying causes of weight gain. As Dr. Cocaul emphasizes, “It’s important to understand why the person has gained weight.” A prescription from a qualified physician is required to obtain these treatments.

Navigating the Risks of Unregulated Purchases

It’s vital to obtain these medications through legitimate channels. Dr. Cocaul cautions against purchasing medications online or seeking shortcuts, emphasizing that there is no “miracle” weight loss solution. Even when a treatment is effective, it should not replace fundamental lifestyle adjustments. “You need to work on diet, sleep, and physical activity,” the specialist insists. Without these accompanying changes, lost weight is likely to return quickly after stopping the medication.

The French National Agency for Medicines and Health Products Safety (ANSM) and Regulation

The conditions for prescribing and dispensing GLP-1 analogues, used in obesity treatment, are evolving in France under the guidance of the ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé). This indicates a proactive approach to managing the use of these powerful medications and ensuring patient safety. The ANSM’s evolving conditions likely address concerns around appropriate patient selection, monitoring for side effects, and long-term efficacy.

Beyond Medication: A Holistic Approach to Weight Management

While medications can be a valuable tool for some individuals, they are not a standalone solution. Successful weight management requires a comprehensive approach that addresses dietary habits, physical activity levels, and overall lifestyle. This includes adopting a balanced diet rich in fruits, vegetables, and lean protein, engaging in regular exercise, and prioritizing sufficient sleep.

Recent research also suggests potential benefits of medications like Ozempic beyond weight loss, including possible effects on conditions like Alzheimer’s disease, addiction, and depression, as reported by The Conversation. However, these findings are preliminary and require further investigation.

What to Expect Moving Forward

The field of obesity treatment is constantly evolving. Ongoing research will likely lead to the development of new medications and improved understanding of existing ones. The ANSM will continue to monitor the safety and efficacy of these treatments, updating guidance as needed. Individuals considering weight loss medications should engage in open and honest conversations with their healthcare providers to determine if these options are appropriate for their specific circumstances and to develop a comprehensive weight management plan.